Traditionally, erythropoiesis-stimulating agents (ESAs) such as recombinant human erythropoietin (rEPO) alfa (epoetin alfa; Eprex®) have been employed to treat anaemia in various conditions such as chronic kidney disease (CKD) and chemotherapy-induced anaemia [4]. Here, EPO is linked to chronic kidney disease.